Abbisko Cayman Limited Announces HK\$522.5 Million Share Placement to Institutional Investors

Abbisko Cayman Limited (Stock Code: 2256), a clinical-stage biopharmaceutical company, has announced a significant fund-raising exercise through the placement of new shares under its general mandate. The deal is structured to bring in gross proceeds of approximately HK\$522.5 million (net proceeds of approximately HK\$517.3 million after deducting commissions and estimated expenses). This is a potentially price-sensitive development with notable implications for the company’s capital structure, ownership, and future strategic initiatives.

Key Highlights of the Placing

• Placing Size: 42,900,000 new shares will be placed, representing approximately 6.37% of the company’s current issued shares (excluding treasury shares), and 5.99% of the enlarged share capital following the placement.
• Placing Price: The shares are priced at HK\$12.18 per share, reflecting a discount of approximately 8.35% to the last closing price (HK\$13.29 as of April 20, 2026) and a 9.31% discount to the five-day average closing price (HK\$13.43 per share).
• Investors: The shares will be placed with no fewer than six reputable institutional investors, all of whom are independent third parties. None will become a substantial shareholder as a result of this transaction.
• Placing Agent: Citigroup Global Markets Limited is acting as the sole overall coordinator and placing agent.
• Mandate: The shares will be allotted and issued under the General Mandate granted by shareholders on June 18, 2025. No additional shareholder approval is required.
• Expected Timetable: The closing of the placing is expected on April 28, 2026, but no later than May 5, 2026.

Use of Proceeds

• 90% (approx. HK\$465.6 million): To be used for research and development of innovative oncology and non-oncology drug candidates, advancement of international multi-centre clinical trials, and potential commercialization activities.
• 10% (approx. HK\$51.7 million): For general and corporate purposes.

Conditions and Lock-Up

• Conditions Precedent: The placing is conditional upon the Stock Exchange granting listing approval for the new shares and a legal opinion confirming the placing is exempt from U.S. SEC registration.
• Lock-Up Undertaking: The company has agreed not to issue, place, or otherwise dispose of additional equity securities for 90 days post-closing without the written consent of the placing agent, except for the issuing of shares under existing share schemes.

Impact on Shareholding Structure

Post-placement, the shareholding of core connected persons (including Dr. Xu Yao-Chang, Dr. Yu Hongping, and Dr. Ji Jing) will be diluted slightly but will remain significant. New placees will collectively hold 5.99% of the enlarged share capital. The public float will remain robust, dropping from 85.18% to 80.08%, while the total number of shares in issue will rise from 673,561,350 to 716,461,350 (excluding treasury shares).

Strategic and Share Price Implications

• Strengthened Financial Position: The substantial inflow of capital will bolster the company’s balance sheet and provide significant resources to accelerate its pipeline development and commercialization efforts.
• Share Dilution: Existing shareholders will experience a dilution of approximately 5.99% in their holdings due to the new shares issued.
• Discounted Placement: The placing price is at a notable discount to the prevailing market price, which may exert short-term downward pressure on the share price.
• No Recent Fundraising: The company has not conducted any equity fundraising in the past twelve months, making this a notable capital event.
• Institutional Participation: The allocation to reputable institutional investors may enhance the company’s profile, broaden its shareholder base, and support long-term share value.

Other Notable Points

• Regulatory Filings: The company will comply with PRC regulations by filing with authorities such as the China Securities Regulatory Commission (CSRC) after the new shares are issued and listed.
• No Substantial Shareholder Change: None of the new placees will become a substantial shareholder, maintaining the current control structure.

Investor Guidance

The completion of the placing is subject to fulfillment of certain conditions precedent and may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

Board Statement

The Board believes the placing will enlarge the shareholder and capital base, strengthen the financial position, and is in the interests of the company and all shareholders as a whole.

Disclaimer

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. The actual completion of the placing is subject to various conditions and may not proceed as described. Investors are urged to read official company disclosures and consult with their financial advisors before making investment decisions. The author does not accept any liability for investment decisions made based on this article.

View ABBISKO-B Historical chart here